Signature
Brenda K. Davis, Attorney-in-Fact
Issuer symbol
RYAM
Transactions as of
03 Mar 2026
Net transactions value
$0
Form type
4
Filing time
05 Mar 2026, 16:44:36 UTC
Previous filing
03 Mar 2026

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Ribeyrolle Christian Antoine Lucien SVP, Biomaterials 1301 RIVERPLACE BOULEVARD, SUITE 2300, JACKSONVILLE Brenda K. Davis, Attorney-in-Fact 05 Mar 2026 0001891056

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RYAM Common Stock Award +4,113 +8.7% $0.000000* 51,477 03 Mar 2026 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares of common stock issued upon the vesting and settlement of Performance Share Units ("PSUs"). The PSUs were originally granted on March 1, 2023 and were subject to performance-based vesting over a three-year performance period ending February 27, 2026, based on (i) relative and absolute Total Shareholder Return ("TSR") metrics and (ii) cumulative adjusted EBITDA performance. On March 3, 2026, the Compensation and Management Development Committee certified the level of achievement of the applicable performance criteria, which certification triggered vesting of the award. The number of shares reported reflects the PSUs earned based on such certified performance results.
F2 PSUs convert into common stock on a one-for-one basis.